{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T21:03:38Z","timestamp":1771880618823,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,5,14]],"date-time":"2014-05-14T00:00:00Z","timestamp":1400025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,5,14]],"date-time":"2014-05-14T00:00:00Z","timestamp":1400025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1007\/s40261-014-0198-x","type":"journal-article","created":{"date-parts":[[2014,5,13]],"date-time":"2014-05-13T07:23:38Z","timestamp":1399965818000},"page":"475-482","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Steady-State Pharmacokinetics of Darunavir\/Ritonavir and Pitavastatin when Co-administered to Healthy Adult Volunteers"],"prefix":"10.1007","volume":"34","author":[{"given":"Christine Y.","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart E.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig A.","family":"Sponseller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Small","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew M.","family":"Medlock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger E.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,5,14]]},"reference":[{"key":"198_CR1","unstructured":"Global AIDS Overview. http:\/\/aids.gov\/federal-resources\/around-the-world\/global-aids-overview\/. Accessed 17 Apr 2014."},{"key":"198_CR2","unstructured":"World Health Organization, Europe, Data and statistics. http:\/\/www.euro.who.int\/en\/health-topics\/communicable-diseases\/hivaids\/data-and-statistics. Accessed 17 Apr 2014."},{"key":"198_CR3","unstructured":"HIV in the United States: at a glance. http:\/\/www.cdc.gov\/hiv\/resources\/factsheets\/us.htm. Accessed 17 Apr 2014."},{"key":"198_CR4","doi-asserted-by":"crossref","unstructured":"Crum NF, Riffenburgh RH, Wegner S, et al for the Triservice AIDS Clinical Consortium. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr. 2006;41:194\u2013200.","DOI":"10.1097\/01.qai.0000179459.31562.16"},{"key":"198_CR5","doi-asserted-by":"crossref","unstructured":"Palella FJ Jr, Baker RK, Moorman AC, et al., for the HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27-34.","DOI":"10.1097\/01.qai.0000233310.90484.16"},{"key":"198_CR6","unstructured":"Go AS, Mozaffarian D, Roger VL, et al on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics\u20142014 update: a report from the American Heart Association. Circulation. 2014;129:e28\u2013e292."},{"key":"198_CR7","first-page":"154","volume":"4","author":"FJ F\u00e9lix-Redondo","year":"2013","unstructured":"F\u00e9lix-Redondo FJ, Grau M, Fern\u00e1ndez-Berg\u00e9s D. Cholesterol and cardiovascular disease in the elderly. Facts and gaps. Aging Dis. 2013;4:154\u201369.","journal-title":"Aging Dis"},{"key":"198_CR8","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.atherosclerosis.2011.06.003","volume":"219","author":"C Giannarelli","year":"2011","unstructured":"Giannarelli C, Klein RS, Badimon JJ. Cardiovascular implications of HIV-induced dyslipidemia. Atherosclerosis. 2011;219:384\u20139.","journal-title":"Atherosclerosis"},{"key":"198_CR9","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.beem.2011.04.004","volume":"25","author":"MP Dub\u00e9","year":"2011","unstructured":"Dub\u00e9 MP, Cadden JJ. Lipid metabolism in treated HIV infection. Best Pract Res Clin Endocrinol Metab. 2011;25:429\u201342.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"198_CR10","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s40262-013-0075-4","volume":"52","author":"B Chauvin","year":"2013","unstructured":"Chauvin B, Drouot S, Barrail-Tran A, Taburet AM. Drug\u2013drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet. 2013;52:815\u201331.","journal-title":"Clin Pharmacokinet"},{"key":"198_CR11","unstructured":"FDA Drug Safety Communication. Interactions between certain HIV or hepatitis C drugs and cholesterol-lowering statin drugs can increase the risk of muscle injury, March 1, 2012. Available from http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm293877.htm. Accessed 17 Oct 2013."},{"key":"198_CR12","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2165\/11207180-000000000-00000","volume":"72","author":"ST Duggan","year":"2012","unstructured":"Duggan ST. Pitavastatin: a review of its use in the management of hypercholesterolemia or mixed dyslipidemia. Drugs. 2012;72:565\u201384.","journal-title":"Drugs"},{"key":"198_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1124\/jpet.104.068056","volume":"311","author":"M Hirano","year":"2004","unstructured":"Hirano M, Maeda K, Shitara Y, et al. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004;311:139\u201346.","journal-title":"J Pharmacol Exp Ther"},{"key":"198_CR14","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1124\/dmd.106.009290","volume":"34","author":"M Hirano","year":"2006","unstructured":"Hirano M, Maeda K, Shitara Y, et al. Drug\u2013drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006;34:1229\u201336.","journal-title":"Drug Metab Dispos"},{"key":"198_CR15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3109\/00498254.2010.523736","volume":"41","author":"MK Choi","year":"2011","unstructured":"Choi MK, Shin HJ, Choi YL, et al. Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica. 2011;41:24\u201334.","journal-title":"Xenobiotica"},{"key":"198_CR16","unstructured":"Prezista\u00ae (darunavir): package insert. Janssen Pharmaceuticals, Inc., Titusville, NJ; 2013."},{"key":"198_CR17","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/QAI.0b013e318251addb","volume":"60","author":"RE Morgan","year":"2012","unstructured":"Morgan RE, Campbell SE, Suehira K, et al. Effects of steady-state lopinavir\/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers. J Acquir Immune Defic Syndr. 2012;60:158\u201364.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"198_CR18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1517\/14740338.2011.540568","volume":"10","author":"TT Abd","year":"2011","unstructured":"Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf. 2011;10:373\u201387.","journal-title":"Expert Opin Drug Saf"},{"key":"198_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","volume":"19","author":"M Schachter","year":"2005","unstructured":"Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19:117\u201325.","journal-title":"Fundam Clin Pharmacol"},{"key":"198_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/0049825021000017957","volume":"33","author":"H Fujino","year":"2003","unstructured":"Fujino H, Yamada I, Shimada S, et al. Metabolic fate of pitavastatin, a new HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica. 2003;33:27\u201341.","journal-title":"Xenobiotica"},{"key":"198_CR21","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1345\/aph.1K615","volume":"42","author":"MM Foisy","year":"2008","unstructured":"Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother. 2008;42:1048\u201359.","journal-title":"Ann Pharmacother"},{"key":"198_CR22","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1177\/0091270011407494","volume":"52","author":"D Samineni","year":"2012","unstructured":"Samineni D, Desai PB, Sallans L, Fichtenbaum CJ. Steady-state pharmacokinetic interactions of darunavir\/ritonavir with lipid-lowering agent rosuvastatin. J Clin Pharmacol. 2012;52:922\u201331.","journal-title":"J Clin Pharmacol"},{"key":"198_CR23","unstructured":"Sekar VJ, Spinosa-Guzman S, Marien K, et al. Pharmacokinetic drug\u2013drug interaction between the new HIV protease inhibitor darunavir (TMC114) and the lipid-lowering agent pravastatin. Eighth International Workshop on Clinical Pharmacology of HIV Therapy. 16\u201318 April 2007, Budapest, Hungary. Abstract 54"},{"key":"198_CR24","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1177\/0091270011427907","volume":"52","author":"CL Aquilante","year":"2012","unstructured":"Aquilante CL, Kiser JJ, Anderson PL, et al. Influence of SLCO1B1 polymorphisms on the drug\u2013drug interaction between darunavir\/ritonavir and pravastatin. J Clin Pharmacol. 2012;52:1725\u201338.","journal-title":"J Clin Pharmacol"},{"key":"198_CR25","first-page":"767","volume":"17","author":"N Nakaya","year":"2001","unstructured":"Nakaya N, Soji N, Kaneko T, et al. Efficacy and safety of NK-104 (pitavastatin), a novel HMG-CoA reductase inhibitor in hypercholesterolemic volunteers. J Clin Ther Med. 2001;17:767\u201387.","journal-title":"J Clin Ther Med"},{"key":"198_CR26","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1086\/521624","volume":"196","author":"Y Mitsuya","year":"2007","unstructured":"Mitsuya Y, Liu TF, Rhee SY, et al. Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment. J Infect Dis. 2007;196:1177\u20139.","journal-title":"J Infect Dis"},{"key":"198_CR27","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/QAI.0b013e318183a959","volume":"49","author":"SM De Meyer","year":"2008","unstructured":"De Meyer SM, Spinosa-Guzman S, Vangeneugden TJ, et al. Efficacy of once-daily darunavir\/ritonavir 800\/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir. J Acquir Immune Defic Syndr. 2008;49:179\u201382.","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-014-0198-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-014-0198-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-014-0198-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-014-0198-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T14:18:01Z","timestamp":1659104281000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-014-0198-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,14]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["198"],"URL":"https:\/\/doi.org\/10.1007\/s40261-014-0198-x","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,14]]},"assertion":[{"value":"14 May 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}